Mid‐regional pro‐adrenomedullin: A rapid sepsis biomarker for diagnosing spontaneous bacterial peritonitis in cirrhosis
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.70021 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Abderrahim Oussalah und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, Division of Biochemistry, Molecular Biology and Nutrition, University Hospital of Nancy, Nancy, France. Hauptthemen laut MEDLINE: Adrenomedullin, Liver Cirrhosis, Peritonitis, Procalcitonin. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Thermo Fisher Scientific (Asnières-sur-Seine, France) generously provided the B.R.A.H.M.S. Sensitive KRYPTOR™ immunofluorescence assays used to measure procalc…, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure, F-54000 Nancy, France, Department of Genomic Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, F-54000 Nancy, France.
Themen: Sepsis
Abstract (Originalsprache)
Background
Spontaneous bacterial peritonitis (SBP) is a frequent and life‐threatening complication of cirrhosis, contributing to considerable morbidity and mortality.
Methods
A cross‐sectional derivation study was conducted to assess the diagnostic accuracy of two sepsis‐related calcitonin peptide family biomarkers, mid‐regional pro‐adrenomedullin (MR‐pro‐ADM) and procalcitonin, in ascitic fluid for identifying bacteriologically confirmed SBP (BC‐SBP). In a subsequent validation study, the diagnostic performance of the ‘SBP score’ was evaluated in an independent patient cohort using an absolute polymorphonuclear (PMN) leukocyte count threshold of ≥250 cells/mm 3 as the diagnostic benchmark for diagnosing SBP.
Results
In the derivation study, the concentration of MR‐pro‐ADM in ascitic fluid was significantly higher in patients with BC‐SBP compared to those without BC‐SBP (3.14 nmol/L [IQR, 2.39–6.74] vs. 1.91 nmol/L [IQR, 1.33–2.80]; p = .0002). Bayesian ANOVA indicated that MR‐pro‐ADM was highly discriminative for diagnosing BC‐SBP, with a substantial Bayes factor (BFM = 2505), whereas procalcitonin exhibited poor discriminatory performance. Receiver‐operating characteristic (ROC) analysis identified an optimal MR‐pro‐ADM cut‐off of ≥2.50 nmol/L for diagnosing BC‐SBP, with an area under the ROC curve (AUROC) of 0.746 (95% CI, 0.685–0.801; p < .0001). Multivariable logistic regression identified three independent predictors of BC‐SBP, which were subsequently incorporated into the ‘SBP score’ (MR‐pro‐ADM ≥2.5 nmol/L, absolute PMN count ≥250 cells/mm 3 and Child–Pugh score). In the validation study, the ‘SBP score’ demonstrated an AUROC of 0.993 (95% CI, 0.929–1.000; p < .0001) for diagnosing SBP.
Conclusion
MR‐pro‐ADM in ascitic fluid emerges as a promising biomarker for SBP diagnosis. Combining MR‐pro‐ADM with absolute PMN count and Child–Pugh score in the ‘SBP score’ greatly improves the diagnostic accuracy of SBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine, Division of Biochemistry, Molecular Biology and Nutrition, University Hospital of Nancy, Nancy, France.
- University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, Nancy, France.
- Department of Gastroenterology and Hepatology, University Hospital of Nancy, Nancy, France.
- Department of Bacteriology, University Hospital of Nancy, Nancy, France.
- Laboratory of Hematology, University Hospital of Nancy, Nancy, France.
- Methodology, Data Management and Statistics Unit, University Hospital of Nancy, Nancy, France.
ORCID-Profile: Abderrahim Oussalah, Maël Silva Rodriguez
Förderung
- Thermo Fisher Scientific (Asnières-sur-Seine, France) generously provided the B.R.A.H.M.S. Sensitive KRYPTOR™ immunofluorescence assays used to measure procalc…
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure, F-54000 Nancy, France
- Department of Genomic Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, F-54000 Nancy, France
Zitieren
APA
Oussalah, A., Haghnejad, V., Silva Rodriguez, M., Lagneaux, A. S., Alix, T., Filhine-Tresarrieu, P., Ferrand, J., Jung, J., Broseus, J., Salignac, S., Luc, A., Baumann, C., Schuetz, P., Lozniewski, A., Peoc'h, K., Puy, H., Guéant, J. L., & Bronowicki, J. P. (2025). Mid‐regional pro‐adrenomedullin: A rapid sepsis biomarker for diagnosing spontaneous bacterial peritonitis in cirrhosis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70021
Vancouver
Oussalah A, Haghnejad V, Silva Rodriguez M, Lagneaux AS, Alix T, Filhine-Tresarrieu P, et al. Mid‐regional pro‐adrenomedullin: A rapid sepsis biomarker for diagnosing spontaneous bacterial peritonitis in cirrhosis. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70021
BibTeX
@article{Oussalah2025,
author = {Oussalah, Abderrahim and Haghnejad, Vincent and Silva Rodriguez, Maël and Lagneaux, Anne-Sophie and Alix, Tom and Filhine-Tresarrieu, Pierre and Ferrand, Janina and Jung, Jean and Broseus, Julien and Salignac, Sylvain and Luc, Amandine and Baumann, Cédric and Schuetz, Philipp and Lozniewski, Alain and Peoc'h, Katell and Puy, Hervé and Guéant, Jean-Louis and Bronowicki, Jean-Pierre},
title = {Mid‐regional pro‐adrenomedullin: A rapid sepsis biomarker for diagnosing spontaneous bacterial peritonitis in cirrhosis},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.70021}
}
EUVIMED